Meltwind is a venture capital firm that focuses its investments on early-stage healthcare and biotech companies. Their strategy involves supporting innovative technologies within sectors like therapeutics, drug discovery, oncology, life sciences tech, and healthcare IT, with the goal of addressing unmet needs and improving drug development.
100% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (50% of deals).
Portfolio
2
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
2 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| EEnhanced Genomics | Series A | $16M | Sep 2025 |
| NNanoSyrinx | Unknown | $12.7M | Sep 2024 |
Top Co-Investors
BGF2 shared
Parkwalk Advisors1 shared
Octopus Ventures1 shared
M Ventures1 shared
Eli Lilly and Company1 shared
IQ Capital1 shared
Last updated: 28 April 2026